Jonathan M. Meyer

Clozapine Handbook (eBook, ePUB)

Stahl's Handbooks

• Format: ePub

Produktbeschreibung

Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Erscheinungstermin: 16. Mai 2019
• Englisch
• ISBN-13: 9781108668422
• Artikelnr.: 62745168

Autorenporträt

Jonathan M. Meyer is currently a Clinical Professor of Psychiatry at the University of California, San Diego and a Psychopharmacology Consultant to the California Department of State Hospitals. Dr Meyer is an internationally recognised speaker on psychopharmacology and the treatment of severe mental illness, and is Distinguished Fellow of the American Psychiatric Association.

Inhaltsangabe

Preface; 1. Initiating Clozapine; 2. Understanding hematologic monitoring and benign ethnic neutropenia; 3. Binding profile
metabolism
kinetics
drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation
orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever
myocarditis
interstitial nephritis
DRESS
serositis and cardiomyopathy; 10. Eosinophilia
leukocytosis
thrombocytopenia
thrombocytosis
anemia
hepatic function abnormalities; 11. Managing enuresis and incontinence
priapism
venous thromboembolism
neuroleptic malignant syndrome
tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia
psychogenic polydipsia
treatment intolerant schizophrenia
suicidality
violence
mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients
elderly patients
patients with intellectual disability
pregnancy and risk for major congenital malformation
lactation
overdose
postmortem redistribution; Index.